Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2025-04-30 Earnings Release
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Earnings Release 2025
Earnings Release Classification · 99% confidence The document contains a table with key financial metrics (Net revenue, Result after tax, Cash flow, Equity ratio, EPS) for periods ending March 31, 2025, and December 31, 2024. It includes a 'Comments from the CEO' section, updates on clinical studies (ReTRIACt), regulatory progress (EU approval, US NDA plans), and a detailed pipeline overview. The presence of quarterly financial data (Jan-Mar 2025) and a comprehensive narrative covering business operations, clinical trials, and outlook strongly indicates this is a periodic financial report covering a shorter period than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) because it contains extensive narrative and detailed financial tables, nor is it the full Annual Report (10-K) as it covers only a quarter. Q1 2025
2025-04-30 English
Annual Report (ESEF) 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-11 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (AGM) for Egetis Therapeutics AB. It contains the agenda, proposals for board elections, remuneration, and instructions for shareholder participation (in-person and advance voting). This document is a proxy statement/notice sent to shareholders to inform them of the upcoming meeting and solicit their votes on specific items, which fits the definition of a Proxy Solicitation & Information Statement.
2025-04-03 English
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice ('Kallelse') for an Annual General Meeting (Årsstämma) for Egetis Therapeutics AB. It contains the agenda, proposals for board elections, remuneration, and voting instructions for shareholders. This document is the official invitation and proxy material for the upcoming AGM, which falls under the category of Proxy Solicitation & Information Statement.
2025-04-03 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-End Report) for the period January-December 2024. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet data, as well as detailed management commentary on business operations, clinical trial updates (ReTRIACt), and strategic outlook. It is a full financial report for a period shorter than a full fiscal year (in the context of the reporting cycle) or a year-end summary, fitting the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis. FY 2024
2025-02-26 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 95% confidence The document is a 'Year-End Report' for the period January-December 2024, containing comprehensive financial statements, management commentary, operational updates, and a financial overview table. It provides substantive financial data and analysis for the full fiscal year, which aligns with the definition of an Interim/Quarterly Report (IR) in the context of a year-end summary report that is not a full 10-K/Annual Report. FY 2024
2025-02-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.